Intestinal absorption, hepatic synthesis, and biliary secretion of cholesterol: Where are we for cholesterol gallstone formation?

Hepatology

Volumn 55, Issue 5, 2012, Pages 1313-1316

  Portincasa, Piero ^a   Wang, David Q H ^b  

^a UNIVERSITY OF BARI MEDICAL SCHOOL   (Italy)

^b SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAMPESTEROL; CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PHYTOSTEROL; SITOSTEROL; URSODEOXYCHOLIC ACID;

BILE; BILIARY EXCRETION; CHOLECYSTECTOMY; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL LIVER LEVEL; CHOLESTEROL STONE; CHOLESTEROL SYNTHESIS; CHOLESTEROL TRANSPORT; CHROMATOGRAPHY; EDITORIAL; GALLSTONE; GENOTYPE; HUMAN; INTESTINE ABSORPTION; MASS SPECTROMETRY; NONHUMAN; PRIORITY JOURNAL; RISK ASSESSMENT;

ATP-BINDING CASSETTE TRANSPORTERS; CHOLESTEROL; FEMALE; GALLSTONES; HUMANS; LIPOPROTEINS; MALE; PHYTOSTEROLS;

EID: 84859929385     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.25604     Document Type: Editorial

References (31)

1. Portincasa P, Moschetta A, Palasciano G. Cholesterol gallstone disease. Lancet 2006; 368: 230-239.
2. Sandler RS, Everhart JE, Donowitz M, Adams E, Cronin K, Goodman C, et al. The burden of selected digestive diseases in the United States. Gastroenterology 2002; 122: 1500-1511.
3. Wang DQH, Cohen DE, Carey MC. Biliary lipids and cholesterol gallstone disease. J Lipid Res 2009; 50( Suppl): S406-S411.
4. Katsika D, Grjibovski A, Einarsson C, Lammert F, Lichtenstein P, Marschall HU. Genetic and environmental influences on symptomatic gallstone disease: a Swedish study of 43, 141 twin pairs. HEPATOLOGY 2005; 41: 1138-1143.
5. Wang DQH, Afdhal NH. Gallstone disease. In: Feldman M, Friedman LS, Brand LJ, eds. Sleisenger and Fordtran's Gastrointestinal and Liver Disease. 9th ed. Philadelphia, PA: Elsevier; 2010: 1089-1120.
6. Portincasa P, Di Ciaula A., Wang HH, Palasciano G, van Erpecum KJ, Moschetta A, et al. Coordinate regulation of gallbladder motor function in the gut-liver axis. HEPATOLOGY 2008; 47: 2112-2126.
7. Wang DQH, Zhang L, Wang HH. High cholesterol absorption efficiency and rapid biliary secretion of chylomicron remnant cholesterol enhance cholelithogenesis in gallstone-susceptible mice. Biochim Biophys Acta 2005; 1733: 90-99.
8. Krawczyk M, Lutjohann D, Schirin-Sokhan R, Villaroel L, Nervi F, Pimentel F, et al. Phytosterol and cholesterol precursor levels indicate increased cholesterol excretion and biosynthesis in gallstone patients. HEPATOLOGY 2012; 55:{black small square}{black small square}{black small square}.
9. de Bari O, Neuschwander-Tetri BA, Liu M, Portincasa P, Wang DQH. Ezetimibe: its novel effects on the prevention and the treatment of cholesterol gallstones and nonalcoholic fatty liver disease. J Lipids 2012; 2012: 302847.
10. Wang HH, Portincasa P, Afdhal NH, Wang DQH. Lith genes and genetic analysis of cholesterol gallstone formation. Gastroenterol Clin North Am 2010; 39: 185-207.
11. Wang HH, Portincasa P, Mendez-Sanchez N, Uribe M, Wang DQH. Effect of ezetimibe on the prevention and dissolution of cholesterol gallstones. Gastroenterology 2008; 134: 2101-2110.
12. Yu L, Hammer RE, Li-Hawkins J, von Bergmann K, Lutjohann D, Cohen JC, et al. Disruption of Abcg5 and Abcg8 in mice reveals their crucial role in biliary cholesterol secretion. Proc Natl Acad Sci USA 2002; 99: 16237-16242.
13. Davis HR Jr, Zhu LJ, Hoos LM, Tetzloff G, Maguire M, Liu J, et al. Niemann-Pick C1 like 1 (NPC1L1) is the intestinal phytosterol and cholesterol transporter and a key modulator of whole-body cholesterol homeostasis. J Biol Chem 2004; 279: 33586-33592.
14. Katsika D, Magnusson P, Krawczyk M, Grunhage F, Lichtenstein P, Einarsson C, et al. Gallstone disease in Swedish twins: risk is associated with ABCG8 D19H genotype. J Intern Med 2010; 268: 279-285.
15. Buch S, Schafmayer C, Volzke H, Becker C, Franke A, von Eller-Eberstein H, et al. A genome-wide association scan identifies the hepatic cholesterol transporter ABCG8 as a susceptibility factor for human gallstone disease. Nat Genet 2007; 39: 995-999.
16. Grunhage F, Acalovschi M, Tirziu S, Walier M, Wienker TF, Ciocan A, et al. Increased gallstone risk in humans conferred by common variant of hepatic ATP-binding cassette transporter for cholesterol. HEPATOLOGY 2007; 46: 793-801.
17. Wang DQH, Tazuma S, Cohen DE, Carey MC. Feeding natural hydrophilic bile acids inhibits intestinal cholesterol absorption: studies in the gallstone-susceptible mouse. Am J Physiol Gastrointest Liver Physiol 2003; 285: G494-G502.
18. Zuniga S, Molina H, Azocar L, Amigo L, Nervi F, Pimentel F, et al. Ezetimibe prevents cholesterol gallstone formation in mice. Liver Int 2008; 28: 935-947.
19. Tang W, Jia L, Ma Y, Xie P, Haywood J, Dawson PA, et al. Ezetimibe restores biliary cholesterol excretion in mice expressing Niemann-Pick C1-like 1 only in liver. Biochim Biophys Acta 2011; 1811: 549-555.
20. Valasek MA, Repa JJ, Quan G, Dietschy JM, Turley SD. Inhibiting intestinal NPC1L1 activity prevents diet-induced increase in biliary cholesterol in Golden Syrian hamsters. Am J Physiol Gastrointest Liver Physiol 2008; 295: G813-G822.
21. Smit JWA, van Erpecum KJ, Stolk MFJ, Geerdink RA, Cluysenaer OJ, Erkelens DW, et al. Successful dissolution of cholesterol gallstone during treatment with pravastatin. Gastroenterology 1992; 103: 1068-1070.
22. Bodmer M, Brauchli YB, Krahenbuhl S, Jick SS, Meier CR. Statin use and risk of gallstone disease followed by cholecystectomy. JAMA 2009; 302: 2001-2007.
23. Turley SD, Dietschy JM. The contribution of newly synthesized cholesterol to biliary cholesterol in the rat. J Biol Chem 1981; 256: 2438-2446.
24. Smit JWA, van Erpecum KJ, Renooij W, Stolk MFJ, Edgar P, Doornewaard H, et al. The effects of the 3-hydroxy, 3-methylglutaryl coenzyme A reductase inhibitor pravastatin on bile composition and nucleation of cholesterol crystals in cholesterol gallstone disease. HEPATOLOGY 1995; 21: 1523-1529.
25. Smit JWA, van Erpecum KJ, Portincasa P, Renooij W, Erkelens DW, vanBerge-Henegouwen GP. Effects of simvastatin and cholestyramine on bile lipid composition and gall bladder motility in patients with hypercholesterolaemia. Gut 1995; 37: 654-659.
26. Davis KG, Wertin TM, Schriver JP. The use of simvastatin for the prevention of gallstones in the lithogenic prairie dog model. Obes Surg 2003; 13: 865-868.
27. Tazuma S, Kajiyama G, Mizuno T, Yamashita G, Miura H, Kajihara T, et al. A combination therapy with simvastatin and ursodeoxycholic acid is more effective for cholesterol gallstone dissolution than is ursodeoxycholic acid monotherapy. J Clin Gastroenterol 1998; 26: 287-291.
28. Sackmann M, Koelbl R, Pauletzki J, Cremer P, Klueppelberg UG, von RC, et al. Simvastatin added to ursodeoxycholic acid does not enhance disappearance of gallstone fragments after shock wave therapy. Z Gastroenterol 1995; 33: 585-589.
29. Attili AF, Carulli N, Roda E, Barbara B, Capocaccia L, Menotti A, et al. Epidemiology of gallstone disease in Italy: prevalence data of the multicenter italian study on cholelithiasis (M.I.C.O.L.). Am J Epidemiology 1995; 141: 158-165.
30. Simonen P, Kotronen A, Hallikainen M, Sevastianova K, Makkonen J, Hakkarainen A, et al. Cholesterol synthesis is increased and absorption decreased in non-alcoholic fatty liver disease independent of obesity. J Hepatol 2011; 54: 153-159.
31. Acton S, Rigotti A, Landschulz KT, Xu S, Hobbs HH, Krieger M. Identification of scavenger receptor SR-BI as a high density lipoprotein receptor. Science 1996; 271: 518-520.